Envíe este artículo por correo electrónico 
Dislipidemia como factor de riesgo para enfermedades cardiovasculares en pacientes con enfermedades autoinmunes
Resumen
Las enfermedades cardiovasculares son la principal causa de muerte en la población general, y los pacientes con enfermedades autoinmunes no son una excepción. Este aumento no puede explicarse exclusivamente por la mayor prevalencia de factores de riesgo cardiovascular en este grupo de pacientes. Una de las causas del aumento del riesgo cardiovascular entre los pacientes con enfermedades autoinmunes puede ser el impacto negativo de estas afecciones en el perfil lipídico. Las pruebas indican que las dislipidemias pueden aumentar el riesgo de enfermedad cardiovascular en la mayoría de las enfermedades autoinmunes. Las alteraciones del perfil lipídico, con cambios en las concentraciones de colesterol total, triglicéridos y lipoproteínas, han sido poco estudiadas como marcadores de riesgo en pacientes con diferentes enfermedades autoinmunes. El objetivo de la investigación fue determinar el papel de la dislipidemia como factor de riesgo de enfermedad cardiovascular en pacientes con enfermedades autoinmunes.
Recibido: 01 de Diciembre de 2024.
Aceptado: 24 de Junio de 2025.
Palabras clave
Texto completo:
PDFReferencias
Song RH, Gao CQ, Zhao J, Zhang JA. An update evolving view of copy number variations in autoimmune diseases. Front Genet. 2022; 12: 794348. [PubMed] [Google Scholar]
Khunsriraksakul C, Markus H, Olsen NJ, Carrel L, Jiang B, Liu DJ. Construction and application of polygenic risk scores in autoimmune diseases. Front Immunol. 2022; 13: 889296. [PubMed] [Google Scholar]
Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015; 278: 69-395. [PubMed] [Google Scholar]
Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune rheumatic diseases and vascular function: The concept of autoimmune atherosclerosis. J
Clin Med. 2021; 10: 4427. [PubMed] [Google Scholar]
Zanatta E, Colombo C, D'Amico G, d'Humières T, Dal Lin C, Tona F. Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases. Int J Mol Sci. 2019; 20: 5563. [PubMed] [Google Scholar]
Zhang G, Cai Y, Liang J, Zhang J, Jing Z, Lv L, Zhang R, Song J, Dang X, Song Q. Causal relationships between rheumatism and dyslipidemia: A two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2022; 13: 961505. [PubMed] [Google Scholar]
Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011; 70: 482-7. [PubMed] [Google Scholar]
Bonek K, Gluszko P. Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach. Reumatologia. 2016; 54: 128-35.
[PubMed] [Google Scholar]
Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014; 53: 2143-54. [PubMed] [Google Scholar]
Aronov A, Kim YJ, Sweiss NJ, Nazir NT. Cardiovascular disease risk evaluation impact in patients with rheumatoid arthritis. Am J Prev Cardiol. 2022; 12: 100380. [PubMed] [Google Scholar]
Chen YJ, Liu SC, Lai KL, Tang KT, Lin CH, Chen YM, Tseng CW, Chang YM, Gotcher DF, Chiou CC, Weng SJ, Chen HH. Factors associated with risk of
major adverse cardiovascular events in patients with rheumatoid arthritis: a nationwide, population-based, casecontrol study. Ther Adv Musculoskelet
Dis. 2021; 13: 1759720X211030809. [PubMed] [Google Scholar]
Pašková U. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis. Ceska Slov Farm. 2019; 68: 219-28. [PubMed]
[Google Scholar]
Papamichail GV, Markatseli TE, Georgiadis AN, Xydis VG, Milionis H, Drosos AA, Voulgari PV. The effects of biologic agents on cardiovascular risk
factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study. Heart Vessels. 2022; 37: 2128-2136. [PubMed] [Google
Scholar]
Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015; 4: e001588. [PubMed] [Google Scholar]
Panda P, Verma HK, Lakkakula S, Merchant N, Kadir F, Rahman S, Jeffree MS, Lakkakula BVKS, Rao PV. Biomarkers of oxidative stress tethered to
cardiovascular diseases. Oxid Med Cell Longev. 2022; 2022: 9154295. [PubMed] [Google Scholar]
Nada D, Gaber R, Mahmoud AS, Elkhouly R, Alashkar D. Hyperuricemia among Egyptian rheumatoid arthritis patients. Is it an association or an inflammatory marker? A cross-sectional observational study. Open Access Rheumatol. 2021; 13: 305-14. [PubMed] [Google Scholar]
Bengtsson K, Forsblad-d'Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, Lindström U, Askling J, Jacobsson LTH. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017; 19: 102. [PubMed] [Google Scholar]
Bhattad PB, Kulkarni M, Patel PD, Roumia M. Cardiovascular morbidity in ankylosing spondylitis: A focus on inflammatory cardiac disease. Cureus. 2022; 14: e25633. [PubMed] [Google Scholar]
Aljohani R. Metabolic syndrome and its components in psoriatic arthritis. Open Access Rheumatol. 2022; 14: 7-16. [PubMed] [Google Scholar]
Olszewski R, Cwiklinska K, Maslinska M, Kwiatkowska B. Prevention and risk assessment of cardiovascular events in a population of patients with psoriasis and psoriatic arthritis. Reumatologia. 2022; 60: 266-74. [PubMed] [Google Scholar]
Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017; 18: 716-24. [PubMed] [Google Scholar]
Riedhammer C, Weissert R. Antigen presentation, autoantigens, and immune regulation in multiple sclerosis and other autoimmune diseases. Front Immunol. 2015; 6: 322. [PubMed] [Google Scholar]
Akama-Garren EH, Miller P, Carroll TM, Tellier M, Sutendra G, Buti L, Zaborowska J, Goldin RD, Slee E, Szele FG, Murphy S, Lu X. Regulation of immunological tolerance by the p53-inhibitor iASPP. Cell Death Dis. 2023; 14: 84. [PubMed] [Google Scholar]
Nanda N, Alphonse MP. From host defense to metabolic signatures: Unveiling the role of ?d T cells in bacterial infections. Biomolecules. 2024; 14: 225. [PubMed] [Google Scholar]
Koh CH, Kim BS, Kang CY, Chung Y, Seo H. IL-17 and IL-21: Their immunobiology and therapeutic potentials. Immune Netw. 2024; 24: e2. [PubMed] [Google Scholar]
Li F, Song B, Zhou WF, Chu LJ. Toll-Like receptors 7/8: A paradigm for the manipulation of immunologic reactions for immunotherapy. Viral Immunol. 2023; 36: 564-78. [PubMed] [Google Scholar]
Buccini DF, Roriz BC, Rodrigues JM, Franco OL. Antimicrobial peptides could antagonize uncontrolled inflammation via Toll-like 4 receptor. Front Bioeng Biotechnol. 2022; 10: 1037147. [PubMed] [Google Scholar]
Zeng F, Zheng J, Shen L, HerreraBalandrano DD, Huang W, Sui Z. Physiological mechanisms of TLR4 in glucolipid metabolism regulation:
Potential use in metabolic syndrome prevention. Nutr Metab Cardiovasc Dis. 2023; 33: 38-46. [PubMed] [Google Scholar]
Azlemany M. The metabolic syndrome, a human disease. Int J Mol Sci. 2024; 25: 2251. [Google Scholar]
Martemucci G, Fracchiolla G, Muraglia M, Tardugno R, Dibenedetto RS, D'Alessandro AG. Metabolic Syndrome: A narrative review from the oxidative stress to the management of related diseases. Antioxidants (Basel). 2023; 12: 2091. [PubMed] [Google Scholar]
Esser N, Paquot N, Scheen AJ. Antiinflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Expert Opin Investig Drugs. 2015; 24: 283-307. [PubMed] [Google Scholar]
Van Rhijn I, van Berlo T, Hilmenyuk T, Cheng TY, Wolf BJ, Tatituri RV, Uldrich AP, Napolitani G, Cerundolo V, Altman JD, Willemsen P, Huang S, Rossjohn J, Besra GS, Brenner MB, Godfrey DI, Moody DB. Human autoreactive T cells recognize CD1b and phospholipids. Proc Natl Acad Sci U S A. 2016; 113: 380-5. [PubMed] [Google Scholar]
Sachinidis A, Nikolic D, Rizzo M, Cianflone D. Psoriasis and acute coronary syndrome risk. Int J Cardiol. 2019; 286: 15-16. [PubMed] [Google
Scholar]
Teklu M, Parel PM, Mehta NN. Psoriasis and cardiometabolic diseases: the impact of inflammation on vascular health. Psoriasis (Auckl). 2021; 11: 99- 108. [PubMed] [Google Scholar]
Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013; 69: 1014-24. [PubMed] [Google Scholar]
Salihbegovic EM, Kurtalic S, Omerkic E. Comorbidity in Men with Psoriasis. Med Arch. 2021; 75: 31-4. [PubMed] [Google Scholar]
Ruiyang B, Panayi A, Ruifang W, Peng Z, Siqi F. Adiponectin in psoriasis and its comorbidities: a review. Lipids Health Dis. 2021; 20: 87. [PubMed] [Google Scholar]
Chan WSA, Liew CF, Theng CTS, Oon HH. Serum adiponectin levels and their association with cardiometabolic risk factors in patients with psoriasis.
Cureus. 2020; 12: e8128. [PubMed] [Google Scholar]
Armstrong A, Bohannan B, Mburu S, Alarcon I, Kasparek T, Toumi J, Frade S, Barrio SF, Augustin M. Impact of psoriatic disease on quality of life: Interim results of a global survey. Dermatol Ther (Heidelb). 2022; 12: 1055-64. [PubMed] [Google Scholar]
Cognasse F, Duchez AC, Audoux E, Ebermeyer T, Arthaud CA, Prier A, Eyraud MA, Mismetti P, Garraud O, Bertoletti L, Hamzeh-Cognasse H. Platelets as key factors in inflammation: Focus on CD40L/CD40. Front Immunol. 2022; 13: 825892. [PubMed] [Google Scholar]
Danese S, Fiocchi C. Atherosclerosis and inflammatory bowel disease: sharing a common pathogenic pathway? Circulation. 2003; 107: e52. [PubMed]
[Google Scholar]
Liu Z, Tang H, Liang H, Bai X, Zhang H, Yang H, Wang H, Wang L, Qian J. Dyslipidaemia is associated with severe disease activity and poor prognosis in ulcerative colitis: A retrospective cohort study in China. Nutrients. 2022; 14: 3040. [PubMed] [Google Scholar]
Wu H, Hu T, Hao H, Hill MA, Xu C, Liu Z. Inflammatory bowel disease and cardiovascular diseases: a concise review. Eur Heart J Open. 2021; 2: oeab029. [PubMed] [Google Scholar]
Michalak A, Kasztelan-Szczerbinska B, Cichoz-Lach H. Impact of obesity on the course of management of inflammatory bowel disease - A review. Nutrients. 2022; 14: 3983. [PubMed] [Google Scholar]
Andersen NN, Jess T. Risk of cardiovascular disease in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2014; 5: 359-65. [PubMed]
[Google Scholar]
Wu H, Xu M, Hao H, Hill MA, Xu C, Liu Z. Endothelial dysfunction and arterial stiffness in patients with inflammatory bowel disease: A systematic review and meta-analysis. J Clin Med. 2022; 11: 3179. [PubMed] [Google Scholar]
Depósito Legal: ppi201102ME3935 - ISSN: 2477-9369.
Copyright ©2012 ULA Todos los derechos reservados
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.